12/23/2010 | CVHYPF | Anadys files $125 million shelf covering stock, preferreds and debt
|
5/26/2010 | PP | New Issue: Anadys Pharmaceuticals plans $12.5 million registered offering of stock
|
5/26/2010 | PP | Market Commentary: Hanmi secures funding from Woori; OceanFreight gets equity infusion; Anadys brings direct sale
|
6/4/2009 | PP | New Issue: Anadys Pharmaceuticals prices $17.5 million placement of stock-and-warrant units
|
4/1/2009 | CVHY | Anadys Pharmaceuticals files $80 million shelf registration
|
12/1/2008 | SS | Adage Capital Partners reports stake of 6.95% in Anadys Pharmaceuticals
|
11/14/2006 | BT | Market Commentary: Acambis plunges on surprise loss of new U.S. vaccine contract bid; World Heart lower; Anadys better
|
11/3/2006 | BT | JMP keeps Anadys at market perform
|
10/18/2006 | BT | Anadys preparing to bring ANA975 back to clinic
|
10/18/2006 | BT | Market Commentary: Trubion gets off, trips on debut; Siga skyrockets 130%; Illumina rises 19.5%; Anadys gains 10%
|
9/6/2006 | BT | Market Commentary: Genta plummets another 41%; Genomic Health falls 17%; Cell Therapeutics up 8%; Anadys up
|
8/9/2006 | BT | JMP reiterates Anadys at market perform
|
7/13/2006 | BT | Market Commentary: Nastech loses 15% on FDA snub; Novavax retreats; Anadys moves up; Acadia slumps; Illumina lifted
|
7/11/2006 | BT | Market Commentary: Connetics stock regains 3%; Anadys adds 8% on new exec, moves Idenix, Vertex up, too; Xoma rises 5%
|
7/5/2006 | BT | Market Commentary: DOV seesaws on CEO exit, closes higher; Neurocrine slides further; Insmed drops 8%; Tercica off 1%
|
6/27/2006 | BT | Market Commentary: Insmed drops 11%; Vasogen up slightly; Anadys falls more; DOV, Discovery Labs up; Genelabs gains
|
6/26/2006 | BT | Anadys suspends dosing in hepatitis C trial pending assessment of preclinical toxicology studies
|
6/26/2006 | BT | JMP cuts Anadys to market perform
|
6/26/2006 | BT | Market Commentary: Vasogen plunges 74%; Anadys falls 45%; Nastech, Amylin gain on pact; Neurocrine finds buyers
|
6/15/2006 | BT | JMP reiterates Anadys at strong buy
|
6/15/2006 | BT | Market Commentary: Nabi rises on renewed pressure; Anadys dives 18%; Discovery Labs surges 26%; Auxilium off
|
6/14/2006 | BT | Anadys president and CEO Kleanthis Xanthopoulos to resign
|
6/6/2006 | BT | Anadys reiterated at strong buy by JMP
|
6/6/2006 | BT | Market Commentary: Xenoport deal emerges; Human Genome up 4%; Anadys, Idenix drop on HGSI news; Onyx up
|
5/26/2006 | BT | Market Commentary: Anadys spikes on thin volume; Cubist extends gain on Cubicin nod; Tanox, Momenta, Epix up
|
5/10/2006 | BT | JMP reiterates Anadys at strong buy
|
5/10/2006 | BT | Market Commentary: Alnylam gains as bird flu names slip; AVI pushes vaccine names lower; Novacea ends flat on debut
|
5/2/2006 | BT | Anadys keeps strong buy rating by JMP
|
3/27/2006 | BTCV | Anadys Pharmaceuticals files $125 million shelf
|
2/24/2006 | BT | Anadys at strong buy by JMP
|
2/14/2006 | BT | Anadys, L.G. Life Sciences report significant viral load reduction using ANA380 in trials
|
1/18/2006 | BT | JMP says select small-, mid-cap biotech stocks look promising
|
1/5/2006 | BT | Market Commentary: Advancis sale of Keflex stumbles; Nuvelo spikes on Bayer pact; buyers snap up Nektar, MannKind
|
12/22/2005 | BT | Anadys to begin phase 1b trial for ANA975 in hepatitis C patients
|
12/13/2005 | BT | Anadys picks ANA 773 for next clinical program
|
11/14/2005 | BT | Anadys Pharmaceuticals study confirms safety of ANA975 for the treatment of hepatitis C
|
11/2/2005 | BT | JMP reiterates Anadys at strong buy
|
8/15/2005 | BT | Biotechnology's solid second quarter a harbinger, Anadys one to watch, JMP Securities report says
|
8/5/2005 | BT | Market Commentary: Advanced Life Sciences IPO gets off at big price cut; AtriCure IPO bounces; Coley's IPO ahead
|
8/4/2005 | BT | Market Commentary: ZymoGenetics follow-on upsized but discounted; Eli Lilly sells $1.5 billion variable floaters
|
8/4/2005 | BT | New Issue: Anadys prices upsized $62 million follow-on offering at $12.40
|
8/3/2005 | BT | Anadys reiterated by JMP at strong buy
|
8/2/2005 | BT | Market Commentary: Anadys up on Novartis details; Ariad, Nastech, ZymoGenetics mixed; Myogen zooms; Isis gains
|
8/1/2005 | BT | Anadys 4 million share follow-on to price after Thursday close, to report 2Q results Tuesday
|
8/1/2005 | BT | Market Commentary: Anadys, Ariad, Nastech offerings join ZymoGenetics for this week; Amgen, Abgenix up on fast track
|